中华口腔医学杂志
中華口腔醫學雜誌
중화구강의학잡지
Chinese Journal of Stomatology
2011年
4期
197-200
,共4页
刘法昱%赵震锦%李鹏%丁雪%孙长伏
劉法昱%趙震錦%李鵬%丁雪%孫長伏
류법욱%조진금%리붕%정설%손장복
趋化因子,CC%癌,鳞状细胞%顺铂%西罗莫司
趨化因子,CC%癌,鱗狀細胞%順鉑%西囉莫司
추화인자,CC%암,린상세포%순박%서라막사
Chemokines,CC%Carcimona,squamous cell%Cisplatin%Siromus
目的 探讨雷帕霉素(rapamycin)与顺铂(cisplatin)联合使用对趋化因子CCL19调节头颈鳞状细胞癌细胞活性的影响.方法 应用甲基噻唑基四唑(MTT)法及流式细胞仪检测顺铂及雷帕霉素对CCL19诱导后人头颈鳞状细胞癌淋巴结转移细胞系(PCI-4B、PCI-37B)生长抑制作用、细胞凋亡作用和细胞周期变化.使用Calcusyn软件计算两种药物(浓度比为80:1)联合使用时的剂量效应参数及联合指数(combination index,CI),使用SPSS 11.0软件包进行统计分析.结果 顺铂及雷帕霉素可以分别提高CCL19作用后细胞的生长抑制率(CCL19+顺铂作用后两细胞系的生长抑制率为21.22%±2.68%和22.76%±2.79%,CCL19+雷帕霉素作用后为19.46%±2.54%和20.6%±4.38%)、细胞G1期比例(CCL19+顺铂作用后两细胞系的G1期比例为72.14%±2.66%和76.39%±1.45%,CCL19+雷帕霉素作用后为75.26%±5.92%和74.00%±1.51%)和凋亡率(CCL19+顺铂作用后两细胞系的凋亡率9.59%±0.86%和7.55%±0.66%,CCL19+雷帕霉素作用后为8.21±1.80%和6.26±0.78%).两种药物浓度比为80:1联合使用时,PCI-4B细胞在半数抑制量(inhibitory concentration 50%,IC50)以下,CI＜1,IC75以上CI＞1;PCI-37B则在IC75以下CI＜1,IC90以上CI＞1.结论 顺铂及雷帕霉素均有抑制CCL19对人头颈鳞状细胞癌淋巴结转移细胞的活性调节作用,并且二者联合使用存在协同作用.
目的 探討雷帕黴素(rapamycin)與順鉑(cisplatin)聯閤使用對趨化因子CCL19調節頭頸鱗狀細胞癌細胞活性的影響.方法 應用甲基噻唑基四唑(MTT)法及流式細胞儀檢測順鉑及雷帕黴素對CCL19誘導後人頭頸鱗狀細胞癌淋巴結轉移細胞繫(PCI-4B、PCI-37B)生長抑製作用、細胞凋亡作用和細胞週期變化.使用Calcusyn軟件計算兩種藥物(濃度比為80:1)聯閤使用時的劑量效應參數及聯閤指數(combination index,CI),使用SPSS 11.0軟件包進行統計分析.結果 順鉑及雷帕黴素可以分彆提高CCL19作用後細胞的生長抑製率(CCL19+順鉑作用後兩細胞繫的生長抑製率為21.22%±2.68%和22.76%±2.79%,CCL19+雷帕黴素作用後為19.46%±2.54%和20.6%±4.38%)、細胞G1期比例(CCL19+順鉑作用後兩細胞繫的G1期比例為72.14%±2.66%和76.39%±1.45%,CCL19+雷帕黴素作用後為75.26%±5.92%和74.00%±1.51%)和凋亡率(CCL19+順鉑作用後兩細胞繫的凋亡率9.59%±0.86%和7.55%±0.66%,CCL19+雷帕黴素作用後為8.21±1.80%和6.26±0.78%).兩種藥物濃度比為80:1聯閤使用時,PCI-4B細胞在半數抑製量(inhibitory concentration 50%,IC50)以下,CI＜1,IC75以上CI＞1;PCI-37B則在IC75以下CI＜1,IC90以上CI＞1.結論 順鉑及雷帕黴素均有抑製CCL19對人頭頸鱗狀細胞癌淋巴結轉移細胞的活性調節作用,併且二者聯閤使用存在協同作用.
목적 탐토뢰파매소(rapamycin)여순박(cisplatin)연합사용대추화인자CCL19조절두경린상세포암세포활성적영향.방법 응용갑기새서기사서(MTT)법급류식세포의검측순박급뢰파매소대CCL19유도후인두경린상세포암림파결전이세포계(PCI-4B、PCI-37B)생장억제작용、세포조망작용화세포주기변화.사용Calcusyn연건계산량충약물(농도비위80:1)연합사용시적제량효응삼수급연합지수(combination index,CI),사용SPSS 11.0연건포진행통계분석.결과 순박급뢰파매소가이분별제고CCL19작용후세포적생장억제솔(CCL19+순박작용후량세포계적생장억제솔위21.22%±2.68%화22.76%±2.79%,CCL19+뢰파매소작용후위19.46%±2.54%화20.6%±4.38%)、세포G1기비례(CCL19+순박작용후량세포계적G1기비례위72.14%±2.66%화76.39%±1.45%,CCL19+뢰파매소작용후위75.26%±5.92%화74.00%±1.51%)화조망솔(CCL19+순박작용후량세포계적조망솔9.59%±0.86%화7.55%±0.66%,CCL19+뢰파매소작용후위8.21±1.80%화6.26±0.78%).량충약물농도비위80:1연합사용시,PCI-4B세포재반수억제량(inhibitory concentration 50%,IC50)이하,CI＜1,IC75이상CI＞1;PCI-37B칙재IC75이하CI＜1,IC90이상CI＞1.결론 순박급뢰파매소균유억제CCL19대인두경린상세포암림파결전이세포적활성조절작용,병차이자연합사용존재협동작용.
Objective To investigate the synergistic effects of rapamycin and cisplatin on head and neck squamous cancer cells regulated by chemokine( C-C motif) ligand 19 (CCL19). Methods The role of rapamycin and cisplatin was detected on cell-cycle and apoptosis in CCL19 induced PCI-4B and PCI-37B cells by methyl thiazolyl tetrazolium (MTT) and flow cytometry(FCM). Dose-effect relationship parameters and combination index(CI) were calculated on the median-effect equation and multiple drug effect equation using computer software CalcuSyn. Statistical analysis was performed by the unpaired student's t-test.Results Rapamycin and cisplatin could respectively increase the growth arrest, the proportion of G1 phase and apoptosis of CCL19 induced cancer cells (P ＜0. 05 ). Under inhibitory concentration 50% (IC50), CI was less than 1, and in IC75, it was more than 1 in PCI-4B cells. In PCI-37B cells, under IC75, CI was less than 1, and in IC90, it was more than 1. Conclusions Rapamycin and cisplatin can inhibit CCL19-regulated PCI-4B and PCI-37B cells' survival. The two drugs have synergistic effects when used in combination.
